What Is a Normal 17-OH Progesterone Level in a Female?

In adult females of reproductive age, a normal serum 17-hydroxyprogesterone (17-OHP) level drawn during the early follicular phase of the menstrual cycle is generally below about 200 ng/dL (roughly 6 nmol/L). That single number, though, hides a lot of important context. Your 17-OHP level shifts with the time of the month, the time of day, your age, whether you’re pregnant, and even the type of lab assay used to measure it. Understanding what “normal” actually means requires knowing which version of normal applies to you.

What 17-OHP Is and Why It Gets Measured

17-hydroxyprogesterone is a steroid hormone produced mainly by the adrenal glands and, to a lesser extent, the ovaries. It sits partway along the biochemical chain that converts cholesterol into cortisol, serving as the raw material for an enzyme called 21-hydroxylase.¹ When that enzyme works properly, 17-OHP gets converted to cortisol without building up. When the enzyme is partially or fully impaired, 17-OHP accumulates in the blood and gets shunted toward androgen production instead. That accumulation is why 17-OHP is the primary screening marker for congenital adrenal hyperplasia (CAH), particularly the form caused by 21-hydroxylase deficiency. But the hormone is also checked in women being evaluated for excess androgen symptoms such as acne, hirsutism, and irregular periods.

How the Menstrual Cycle Affects Your Levels

If you’re a woman of reproductive age, your 17-OHP level depends heavily on where you are in your menstrual cycle. During the first twelve or so days of the follicular phase, levels stay relatively low and stable. A study tracking salivary hormone concentrations across full cycles in healthy young women found that 17-OHP remained in a narrow low range through day 12, then climbed sharply around ovulation, peaking between days 14 and 17 before dropping back down.² That midcycle surge occurs because the ovary itself produces 17-OHP around ovulation. In the luteal phase, levels can remain modestly elevated before declining toward the next period.

This is why doctors prefer to draw 17-OHP during the early follicular phase, ideally within the first five days of the cycle. A sample taken at ovulation or during the luteal phase can easily come back above the reference range without anything being wrong. If your result seems borderline and the blood was drawn at an uncertain point in your cycle, your doctor may want to repeat it at a better time.

The Morning Factor

17-OHP follows a daily rhythm that roughly parallels cortisol. Levels are highest in the early morning hours and taper off as the day goes on. Research has documented this pattern clearly, with peak concentrations measured around 8:00 AM.³ This matters because screening tests for nonclassical CAH are most sensitive when drawn in the morning. One study of patients with confirmed nonclassical 21-hydroxylase deficiency found that early-morning salivary 17-OHP was substantially higher than levels measured just a couple of hours later, while healthy controls showed no such swing.⁴ If you’re getting tested to rule out an enzyme deficiency, a blood draw around 7–9 AM in the early follicular phase gives the clearest picture.

Levels During Pregnancy

Pregnancy dramatically changes the picture. The placenta becomes an additional source of 17-OHP, and levels follow a distinctive U-shaped curve. In one study tracking pregnant women from early gestation through delivery, average plasma 17-OHP hit about 3.7 ng/mL around week seven, then gradually declined to roughly 0.5 ng/mL between weeks 14 and 34, before climbing again to about 2 ng/mL by week 40.⁵ A separate longitudinal study reported that 17-OHP concentrations in serum increase roughly threefold across pregnancy overall.⁶

These elevated levels are entirely normal in pregnancy and should not be mistaken for a sign of adrenal disease. However, for women already known to have CAH, monitoring 17-OHP during pregnancy can help guide glucocorticoid dosing. The standard non-pregnant reference ranges simply do not apply.

Levels in Children and Adolescents

Pediatric reference ranges look very different from adult ones and shift rapidly in the first months of life. In one large study using mass spectrometry, the widest range was found in infants under six months, with 17-OHP spanning 25 to 248 ng/dL. Beyond six months, values dropped, and the upper end of normal for older children was well below that infant range. In adolescent girls aged 10 to 18, the reference interval was 15 to 137 ng/dL, which was actually higher than the range for girls under 10 and also higher than for boys of the same age.⁷ That adolescent rise reflects the activation of adrenal and ovarian steroid production during puberty. A more recent study using LC-MS/MS confirmed that sex- and age-specific fluctuations during minipuberty, puberty, and the menopausal transition all influence what counts as normal.⁸

The neonatal period presents a particular challenge. Newborn screening programs worldwide use 17-OHP to detect classic CAH, but preterm and low-birth-weight babies often have transiently elevated levels that trigger false-positive results.⁹ Respiratory distress, early specimen collection, and lower gestational age all push 17-OHP higher in newborns without any underlying enzyme deficiency.¹⁰ Most screening programs now adjust their cutoffs based on birth weight or gestational age to reduce unnecessary follow-up.

Why the Lab Method Matters More Than You’d Expect

Not all 17-OHP assays measure the same thing with the same accuracy, and this can genuinely change whether your result is reported as normal or elevated. The traditional approach uses immunoassays, which are fast and widely available but have a well-known weakness: they can cross-react with other structurally similar steroid molecules in the blood. This cross-reactivity tends to push 17-OHP readings higher than the true value. In newborn screening, cross-reactivity with steroid sulfates is one of the main drivers of false-positive results.¹¹

Liquid chromatography-tandem mass spectrometry (usually abbreviated LC-MS/MS) is a newer, more specific method that avoids this problem by separating 17-OHP from look-alike molecules before measuring it. When researchers compared the two methods on patient blood spot samples, the correlation was poor, while the same comparison on quality-control samples (which lack the interfering substances found in real patient blood) showed excellent agreement.¹² In New Zealand, switching from an immunoassay second-tier test to LC-MS/MS reduced false positives in newborn screening from 172 to 40 over a two-year period, and the positive predictive value jumped from under 2% to over 11%.¹³

For adult women being screened for nonclassical CAH, the assay type can also shift the diagnostic cutoff. One study found that the optimal baseline 17-OHP cutoff for identifying nonclassical CAH was about 6 nmol/L when measured by radioimmunoassay but roughly 8 nmol/L when measured by ELISA, because the two platforms produce systematically different numbers.¹⁴ If your result sits near a cutoff, it’s worth asking which assay your lab used.

When an Elevated 17-OHP Suggests an Underlying Condition

A 17-OHP above the normal range points the clinician toward a handful of possibilities, the most common being congenital adrenal hyperplasia in its nonclassical form (NCCAH). This milder version of the enzyme deficiency often doesn’t show up until adolescence or adulthood, and symptoms can overlap heavily with polycystic ovary syndrome (PCOS): acne, excess body hair, and irregular periods. In one study of women with persistent acne, elevated 17-OHP was found in a striking proportion, and those with the highest levels were more likely to also have PCOS features.¹⁵

Distinguishing NCCAH from PCOS matters because the treatment approach differs. Research comparing the two conditions found that a baseline serum 17-OHP above about 5.4 ng/mL had 100% specificity for identifying NCCAH over PCOS.¹⁶ Below that threshold, the overlap between the two conditions widens, and further testing is usually needed.

Less commonly, elevated 17-OHP can come from an adrenal or ovarian tumor that produces the hormone directly. Case reports have described benign adrenal adenomas with steroidogenesis defects that mimic NCCAH on routine labs, sometimes leading to an initial misdiagnosis of CAH.¹⁷ When 17-OHP is unexpectedly high and doesn’t respond to treatment in the typical way, imaging of the adrenal glands is usually the next step.¹⁸

The ACTH Stimulation Test

When a baseline 17-OHP is borderline or equivocal, clinicians often turn to the cosyntropin (ACTH) stimulation test. This involves injecting synthetic ACTH and measuring 17-OHP thirty to sixty minutes later. In a person with normal 21-hydroxylase activity, the rise in 17-OHP is modest. In someone with even partial enzyme impairment, the adrenal glands produce an exaggerated spike because the backed-up substrate has nowhere efficient to go. A stimulated 17-OHP above about 10 nmol/L (roughly 330 ng/dL) is a commonly used threshold for distinguishing people who carry one copy of a CYP21A2 mutation from those with no mutations.¹⁹

One thing worth knowing is that some women with PCOS also show an exaggerated 17-OHP response to ACTH stimulation, but research suggests this is often because their baseline 17-OHP was already elevated from ovarian overproduction, and the normal adrenal increment simply adds onto that higher starting point.²⁰ For this reason, looking at the size of the increase after stimulation, rather than only the peak value, can help avoid false attributions to an adrenal enzyme problem.

In clinical practice, a stimulated 17-OHP above about 30 nmol/L (roughly 1,000 ng/dL) is highly suggestive of NCCAH, while results between about 10 and 30 nmol/L may indicate carrier status for a CYP21A2 mutation. The diagnosis is then confirmed with genetic testing. Using an LC-MS/MS-based assay, one study found that a baseline 17-OHP of 6 nmol/L served as an effective screen: almost all confirmed NCCAH patients had baselines above that level.²¹

What It Means to Be a Carrier

Around 1 in 15 to 1 in 50 people (depending on the population) carry a single mutated copy of the CYP21A2 gene. These carriers typically don’t have classic or nonclassical CAH, but their 17-OHP levels aren’t quite the same as in non-carriers either. Studies comparing carriers to both non-carriers and NCCAH patients have consistently found that carriers fall in between: their baseline and ACTH-stimulated 17-OHP levels are higher than average but lower than in full NCCAH.²² In general, carriers do not develop a serious endocrine disorder, though some may exhibit mild hyperandrogenic features like acne or hirsutism.²³

Carrier status matters most in reproductive planning. If both partners carry a CYP21A2 mutation, there is a chance their children could have classic or nonclassical CAH. A woman whose 17-OHP is borderline and whose stimulation test falls in the carrier range may be offered genetic testing for this reason, particularly if she’s planning a pregnancy.

How Oral Contraceptives and Stress Affect Results

Birth control pills containing estrogen and progestin suppress ovarian steroid production, and that includes 17-OHP. Women on combined oral contraceptives tend to have lower plasma concentrations of several adrenal and ovarian steroids compared to women not on the pill.²⁴ Research in women with PCOS found that an oral contraceptive containing drospirenone significantly reduced 17-OHP levels.²⁵ This means that if you’re tested while on hormonal contraception, your 17-OHP may be artificially low, potentially masking NCCAH. Most guidelines recommend stopping oral contraceptives for at least four to six weeks before diagnostic 17-OHP testing if an enzyme deficiency is being considered.

Physical and surgical stress can push 17-OHP in the opposite direction. Research on the adrenal stress response has shown that 17-OHP levels rise during surgery under general anesthesia.²⁶ Any acute illness, significant physical stress, or recent procedure can transiently raise your level. If a blood draw happens during one of these episodes, a mildly elevated result may not mean much on its own.

17-OHP and Fertility

Elevated 17-OHP has direct implications for reproductive function, particularly in women with CAH. The excess 17-OHP gets converted to progesterone, and elevated progesterone during the follicular phase can interfere with normal follicle development and endometrial receptivity, making it harder to conceive or maintain a pregnancy. In women with classic CAH, the degree of menstrual irregularity correlates with how effectively glucocorticoid treatment suppresses adrenal overproduction. Some women with CAH who achieve suppression of 17-OHP still have elevated progesterone from other metabolic routes, which can cause persistent amenorrhea.²⁷

Treatment for fertility in these cases often involves careful dose adjustments. In one reported case, switching from hydrocortisone to dexamethasone achieved better suppression of adrenal progesterone, which enabled a successful pregnancy through assisted reproduction.²⁸ For women with NCCAH trying to conceive, monitoring 17-OHP alongside progesterone helps clinicians judge whether adrenal suppression is adequate for normal ovulatory function.

Quick-Reference Ranges by Life Stage

Because unit confusion is rampant in this area, here is an approximate overview of where levels tend to fall across different stages of a woman’s life. Keep in mind that individual labs may report slightly different ranges depending on their assay.

• Newborns (0–6 months): 25–248 ng/dL, with the widest normal range of any age group due to immature adrenal function and residual maternal hormones.
• Prepubertal girls (6 months–10 years): Generally lower than the infant range, often below 50–80 ng/dL at the upper end.
• Adolescent girls (10–18 years): 15–137 ng/dL, reflecting the onset of adrenal and ovarian steroid production.
• Adult women, early follicular phase: Typically under 200 ng/dL (about 6 nmol/L or 2 ng/mL). Many labs cite an upper limit closer to 100–150 ng/dL for this phase.
• Adult women, midcycle/luteal phase: Levels rise transiently and can exceed the follicular-phase upper limit without being abnormal.
• Pregnancy: Ranges shift dramatically; levels can reach 370 ng/dL (3.7 ng/mL) in the first trimester and around 200 ng/dL (2 ng/mL) near term.
• Postmenopause: Levels generally decline as ovarian contribution drops, though adrenal production continues.

These values apply to morning blood draws. An afternoon sample at any life stage will likely be lower. And as discussed, the assay platform can shift results by enough to change their interpretation near a cutoff.

Adrenal Incidentalomas and Unexpected 17-OHP Elevation

Occasionally, elevated 17-OHP shows up as a surprise finding during a workup for something else entirely. One clinical scenario involves adrenal incidentalomas, tumors discovered on imaging done for an unrelated reason. Some of these tumors have their own impaired steroidogenesis, producing excess 17-OHP without the patient carrying CYP21A2 mutations. In one study evaluating patients with adrenal incidentalomas, researchers used ACTH stimulation to look for impaired 21-hydroxylase activity and defined an exaggerated response as a 17-OHP increment exceeding 7.9 nmol/L above baseline.²⁹ These cases are rare, but they highlight why persistent or unexplained 17-OHP elevation sometimes warrants imaging rather than only genetic testing.³⁰